Arecor Announces Transfer Of Novel Therapeutic Product To Hikma
FTSE 250 company Hikma have triggered the transfer of Arecors’s AT307 product including a milestone payment.
FTSE 250 company Hikma have triggered the transfer of Arecors’s AT307 product including a milestone payment.
Calculus CEO, John Glencross, gives an update on the happenings in Q4 2022.
Home Team will develop and produce premium television projects with UIS for the UK and global market
C4X Discovery continues its progress with the signing of an exclusive global license with AstraZeneca.
Calculus completes exit from Avvio for 5.5x return, a continuation of excellent exits achieved for Calculus investors in the last two years.
The Government is committed to helping entrepreneurial businesses raise growth capital by continued support of EIS and VCT
Destiny Pharma’s potentially revolutionary product ‘XF-73’ progresses into next stage study.